FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086011692> ?p ?o ?g. }

• W2086011692 endingPage "204" @default.
• W2086011692 startingPage "195" @default.
• W2086011692 abstract "Reduced levels of membrane essential polyunsaturated fatty acids (EPUFAs), namely, arachidonic acid (AA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acids (DHAs), and their association with psychopathology have been consistently reported in both chronic-medicated schizophrenic patients as well as in never-medicated patients soon after the first episode of psychosis. Past supplementation studies with either ω-6 or ω-3 or both EPUFAs generally in chronic-medicated-older patients have reported varying degrees of therapeutic effects, and have suggested that supplementation with primarily ω-3 EPUFAs (EPA>DHA) may be preferable. We report the supplementation with a mixture of EPA/DHA (180:120 mg) and antioxidants (vitamin E/C, 400 IU:500 mg) orally morning and evening to schizophrenic patients (N=33) for 4 months. The red blood cell (RBC) membrane fatty acid levels, plasma lipid peroxides and clinical measures were carried out by established procedures at pretreatment, posttreatment and after 4 months of postsupplementation period to determine the stability of treatment effects within patients. Levels of fatty acids and lipid peroxides were compared with their levels in normal controls (NC) (N=45). Posttreatment levels of RBC EPUFAs were significantly higher than pretreatment levels as well as levels in normal controls without any significant increase in plasma peroxides. Concomitantly, there was significant reduction in psychopathology based on reduction in individual total scores for brief psychiatric rating scale (BPRS) and positive and negative syndrome scale (PANSS), general psychopathology-PANSS and increase in Henrich's Quality of Life (QOL) Scale. The EPUFA levels returned to pretreatment levels after 4 months of supplementation washout. However, the clinical improvement was significantly retained. Future studies need be done in placebo-controlled trials and also with a comparison group supplemented with fatty acids alone in a larger number of patients, both chronic as well as never medicated, and for a longer duration of treatment while the dietary intake is monitored. This may establish the EPUFA supplementation a very effective treatment to improve the outcome for an extended period of time." @default.
• W2086011692 created "2016-06-24" @default.
• W2086011692 creator A5013728674 @default.
• W2086011692 creator A5033106678 @default.
• W2086011692 creator A5045968084 @default.
• W2086011692 creator A5049536098 @default.
• W2086011692 creator A5060183607 @default.
• W2086011692 date "2003-08-01" @default.
• W2086011692 modified "2023-09-28" @default.
• W2086011692 title "Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia" @default.
• W2086011692 cites W147183711 @default.
• W2086011692 cites W1568124887 @default.
• W2086011692 cites W1965278340 @default.
• W2086011692 cites W1966015120 @default.
• W2086011692 cites W1969217470 @default.
• W2086011692 cites W1975367652 @default.
• W2086011692 cites W1975464025 @default.
• W2086011692 cites W1983398680 @default.
• W2086011692 cites W1991506996 @default.
• W2086011692 cites W1993059939 @default.
• W2086011692 cites W1995166208 @default.
• W2086011692 cites W1996015317 @default.
• W2086011692 cites W2018196228 @default.
• W2086011692 cites W2020844317 @default.
• W2086011692 cites W2022590057 @default.
• W2086011692 cites W2024285057 @default.
• W2086011692 cites W2033208205 @default.
• W2086011692 cites W2034194523 @default.
• W2086011692 cites W2042212205 @default.
• W2086011692 cites W2059809898 @default.
• W2086011692 cites W2060878115 @default.
• W2086011692 cites W2070106764 @default.
• W2086011692 cites W2081609269 @default.
• W2086011692 cites W2087962937 @default.
• W2086011692 cites W2093015590 @default.
• W2086011692 cites W2118700259 @default.
• W2086011692 cites W2119138947 @default.
• W2086011692 cites W2131417790 @default.
• W2086011692 cites W2140606211 @default.
• W2086011692 cites W2145336951 @default.
• W2086011692 cites W2149639459 @default.
• W2086011692 cites W2152692585 @default.
• W2086011692 cites W2156733305 @default.
• W2086011692 cites W2159011576 @default.
• W2086011692 cites W2165122693 @default.
• W2086011692 cites W2337943738 @default.
• W2086011692 cites W253326700 @default.
• W2086011692 cites W600305827 @default.
• W2086011692 cites W2480157670 @default.
• W2086011692 cites W2523105604 @default.
• W2086011692 doi "https://doi.org/10.1016/s0920-9964(02)00284-0" @default.
• W2086011692 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12837515" @default.
• W2086011692 hasPublicationYear "2003" @default.
• W2086011692 type Work @default.
• W2086011692 sameAs 2086011692 @default.
• W2086011692 citedByCount "247" @default.
• W2086011692 countsByYear W20860116922012 @default.
• W2086011692 countsByYear W20860116922013 @default.
• W2086011692 countsByYear W20860116922014 @default.
• W2086011692 countsByYear W20860116922015 @default.
• W2086011692 countsByYear W20860116922016 @default.
• W2086011692 countsByYear W20860116922017 @default.
• W2086011692 countsByYear W20860116922018 @default.
• W2086011692 countsByYear W20860116922019 @default.
• W2086011692 countsByYear W20860116922020 @default.
• W2086011692 countsByYear W20860116922021 @default.
• W2086011692 countsByYear W20860116922022 @default.
• W2086011692 countsByYear W20860116922023 @default.
• W2086011692 crossrefType "journal-article" @default.
• W2086011692 hasAuthorship W2086011692A5013728674 @default.
• W2086011692 hasAuthorship W2086011692A5033106678 @default.
• W2086011692 hasAuthorship W2086011692A5045968084 @default.
• W2086011692 hasAuthorship W2086011692A5049536098 @default.
• W2086011692 hasAuthorship W2086011692A5060183607 @default.
• W2086011692 hasConcept C118552586 @default.
• W2086011692 hasConcept C123273963 @default.
• W2086011692 hasConcept C126322002 @default.
• W2086011692 hasConcept C134018914 @default.
• W2086011692 hasConcept C181199279 @default.
• W2086011692 hasConcept C185592680 @default.
• W2086011692 hasConcept C19038510 @default.
• W2086011692 hasConcept C2776091944 @default.
• W2086011692 hasConcept C2776412080 @default.
• W2086011692 hasConcept C2777171753 @default.
• W2086011692 hasConcept C2777551382 @default.
• W2086011692 hasConcept C2778004101 @default.
• W2086011692 hasConcept C2778078955 @default.
• W2086011692 hasConcept C2779727114 @default.
• W2086011692 hasConcept C2780135775 @default.
• W2086011692 hasConcept C2781349093 @default.
• W2086011692 hasConcept C543025807 @default.
• W2086011692 hasConcept C55493867 @default.
• W2086011692 hasConcept C71924100 @default.
• W2086011692 hasConceptScore W2086011692C118552586 @default.
• W2086011692 hasConceptScore W2086011692C123273963 @default.
• W2086011692 hasConceptScore W2086011692C126322002 @default.
• W2086011692 hasConceptScore W2086011692C134018914 @default.
• W2086011692 hasConceptScore W2086011692C181199279 @default.

• next